Anti-fungal Drugs Market Trends

Statistics for the 2023 & 2024 Anti-fungal Drugs market trends, created by Mordor Intelligence™ Industry Reports. Anti-fungal Drugs trend report includes a market forecast to 2029 and historical overview. Get a sample of this industry trends analysis as a free report PDF download.

Market Trends of Anti-fungal Drugs Industry

Azoles Segment Expected to Witness Significant Growth During the Forecast Period

  • The azole group of compounds are antifungal agents that have greatly expanded therapeutic options for treating systemic fungal infections. Research in the field of fungal drugs is growing rapidly, thanks to the development of new antifungal drugs using the azole group. Synthetic azoles and semi-synthetic compounds are widely used for fungal infections, and as a result, the segment is expected to experience significant growth over the analysis period.
  • Azole group drugs are used to treat a variety of fungal infections, including thrush, yeast infections, candidiasis, aspergillosis, tinea versicolor, athlete's foot, jock itch, ringworm, systemic mycosis, and seborrheic dermatitis. The azole antifungal group includes two phases: triazoles (fluconazole, itraconazole, voriconazole, posaconazole, and isavuconazole) and imidazoles (ketoconazole).
  • Triazoles have a wide range of applications in the treatment of external fungal infections and systemic infections. The azole group provides a broad spectrum of activity and improved safety standards. These medications have fewer side effects, fewer drug interactions, and improved absorption and distribution properties. These benefits of azoles have contributed to their superiority over other components, further fueling the growth of the segment.
  • In addition, the development and innovation of such potential drugs promote the competitiveness of the pharmaceutical market. In October 2021, Intas Pharmaceuticals Limited launched an innovative antifungal drug, Super Bioavailable Itraconazole-SB 100 mg, under the brand name Itaspor-SB Forte/Subawin.
  • Furthermore, in June 2021, Cadila Pharmaceuticals introduced a new triazole antifungal drug, Posaconazole, which is effective against a wide range of invasive fungal diseases. The drug has also been recommended as a second-line treatment for Mucormycosis. Such advancements are expected to drive the growth of the segment during the forecast period.
Anti-fungal Drugs Market: Estimated Annual Burden of Fungal Infections (in thousands), By Type, Global, 2021

North America Expected to Hold a Significant Share of the Market

  • North America holds a significant share of the market under study and is expected to maintain its strong position during the analysis period. This growth can be attributed to factors such as the increasing burden of fungal infections among the target population and rising company activities for product development across the countries in the region.
  • The United States is one of the most economically developed countries in the region, among other countries such as Canada and Mexico. However, fungal infections in the country have presented challenges to health authorities. According to data updated by the Centers for Disease Control and Prevention (CDC) in June 2022, Candida was a common cause of blood-related infections in the United States, and a few drug-resistant strains were also prevalent in the country. Hence, there is a growing need for anti-fungal drugs in the United States.
  • Additionally, there have been recent outbreaks of fungal infections in Canada, which have fueled the need for anti-fungal drugs for treatment. For example, in September 2022, as per a press release by Quebec's health ministry, the department dispatched infection control teams to Pierre Boucher Hospital in Longueuil to combat the first-ever outbreak of a potentially deadly fungus, "Candida auris," in Quebec. Candida auris is a type of yeast that can cause severe illness. When it is found in any healthcare setting, it is more dangerous for admitted patients and caregivers. These instances and the burden of infections have created a potential need for the availability of anti-fungal drugs and are expected to contribute to the growth of the studied market in the region.
  • Moreover, product approvals and launches by market players are further creating competition in the market. For instance, in June 2021, Scynexis announced the FDA approval of Brexafemme for the treatment of vaginal yeast infections. In addition, in January 2021, Sandoz Canada Inc. launched PrSandoz Posaconazole, making Sandoz the first company to offer posaconazole generics on the Canadian market. Sandoz Posaconazole is used to treat Aspergillus fungal infections and to prevent fungal infections caused by Aspergillus and Candida, especially in oncology patients with a history of stem cell transplant. Such company activities and the burden of fungal infections are anticipated to accelerate the growth of the studied market in the region over the forecast period.
: Anti-fungal Drugs Market - Growth Rate by Region

Anti-Fungal Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)